Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine
- Development stage
- Phase 4
- Lead developer
- Panacea Biotec
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Bivalent oral poliovirus vaccine (bOPV) is a live attenuated viral vaccine administered orally to protect against poliomyelitis caused by poliovirus types 1 and 3. It does not provide protection against type 2 poliovirus. The mechanism of action involves stimulating both intestinal and systemic immunity by introducing weakened forms of the virus, which elicit an immune response without causing disease. In April 2016, bOPV replaced trivalent OPV in global immunization programs after wild type 2 poliovirus was declared eradicated. The primary indication for bOPV is the prevention of paralytic polio as part of routine childhood immunization schedules[1][3][5][8].
- Brand names
- Bi-OPV
- Other names
- bOPVbivalent OPVoral polio vaccine type 1 and 3
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine.